A Feasibility Study of Ketorolac Treatment for Cachexia in Patients With Advanced Pancreatic Ductal Adenocarcinoma

NCT ID: NCT05336266

Last Updated: 2026-01-06

Basic Information

• Recruitment Status: ACTIVE_NOT_RECRUITING
• Clinical Phase: EARLY_PHASE1
• Total Enrollment: 28 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-07-01
• Study Completion Date: 2026-12-05

Brief Summary

The purpose of this study is to see if taking ketorolac, a nonsteroidal anti-inflammatory drug (NSAID), is reasonable, safe and can stabilize or increase weight along with quality of life in pancreatic cancer patients.

Detailed Description

The main things that will happen in this study are: patients will be administered ketorolac for 5 days, blood draws, completion of questionnaires, monitoring physical activity and sleep by wearing a study-provided FitBit along with weight using a study-provided smart scale.

Conditions

Pancreas Cancer; Pancreatic Ductal Adenocarcinoma; Pancreatic Cancer

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: SUPPORTIVE_CARE
• Blinding Strategy: NONE

Study Groups

Ketorolac (open label)

Pancreatic patients receiving Ketorolac four times a day for up to five days

Group Type: EXPERIMENTAL

Ketorolac Tromethamine

Intervention Type: DRUG

Trial treatment of ketorolac 10mg orally four times a day for 5 consecutive days

Interventions

Ketorolac Tromethamine

Trial treatment of ketorolac 10mg orally four times a day for 5 consecutive days

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Diagnosis of advanced and refractory pancreatic ductal adenocarcinoma (PDAC) referred to Cedars-Sinai Medical Center (CSMC).

2. Cachexia defined as ≥5% weight loss in the presence of chronic illness, within any 6-month period prior to screening or as documented by the medical physician based on standard diagnosis of cachexia.

3. Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2 or Karnofsky performance status >50%.

4. Patient must have adequate renal function per below lab values:

• Creatinine OR measured or calculated creatinine clearance (glomerular filtration rate can also be used in place of creatinine or CrCl) ≤1.5 × upper limit of normal OR ≥30 mL/min for participant with creatinine levels >1.5 × institutional ULN.

5. Patient must have access to WiFi for the Smart Scale.

Exclusion Criteria

1. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements in the opinion of the investigator.

2. Pregnancy, breastfeeding, or of childbearing potential and not willing to use adequate methods of contraception during the study.

3. Has any known allergies or hypersensitivity to the study drug or allergic reactions to surgical steel or elastomer/rubber.

4. Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.

5. Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.

6. Concurrent use of any other NSAIDs while on study.

7. Active peptic ulcer disease, recent gastrointestinal bleeding or perforation, or a history of peptic ulcer disease or gastrointestinal bleeding.

8. Have suspected or confirmed cerebrovascular bleeding, tendency to bleed or bruise easily, incomplete hemostasis (how you body stops bleeding), and at high risk of bleeding.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Yinuoke Ltd.

UNKNOWN

Sponsor Role: collaborator

Andrew Hendifar, MD

OTHER

Sponsor Role: lead

Responsible Party

Andrew Hendifar, MD

Assistant Professor, Medicine

Responsibility Role: SPONSOR_INVESTIGATOR

Principal Investigators

Andrew Hendifar, MD

Role: PRINCIPAL_INVESTIGATOR

Cedars-Sinai Medical Center

Locations

Cedars- Sinai Medical Center

Los Angeles, California, United States

Countries

United States

Other Identifiers

IIT2021-16-HENDIFAR-KETOROCX

Identifier Type: -

Identifier Source: org_study_id